Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs

被引:21
|
作者
Finlay, Andrea K. [1 ,2 ]
Ellerbe, Laura S. [1 ]
Wong, Jessie J. [1 ,3 ]
Timko, Christine [1 ,3 ]
Rubinsky, Anna D. [4 ,5 ]
Gupta, Shalini [1 ]
Bowe, Thomas R. [1 ]
Burden, Jennifer L. [6 ]
Harris, Alex H. S. [1 ,7 ]
机构
[1] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA
[2] Dept Vet Affairs, Natl Ctr Homelessness Vet, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA
[3] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd, Menlo Pk, CA 94025 USA
[4] Univ Calif San Francisco, Kidney Hlth Res Collaborat, 500 Parnassus Ave, San Francisco, CA 94143 USA
[5] San Francisco VA Med Ctr, 500 Parnassus Ave, San Francisco, CA 94143 USA
[6] Vet Hlth Adm, Dept Vet Affairs, 1970 Roanoke Blvd,116A, Salem, VA 24153 USA
[7] Stanford Univ, Sch Med, Dept Surg, Alway Bldg,Room M121,300 Pasteur Dr, Stanford, CA 94305 USA
关键词
Alcohol-related disorders; Alcohol dependence; Pharmacotherapy; Veterans; Residential treatment; MENTAL-HEALTH; VETERANS; IMPLEMENTATION; DEPENDENCE; SETTINGS;
D O I
10.1016/j.jsat.2017.03.005
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Among US military veterans, alcohol use disorder (AUD) is prevalent and in severe cases patients need intensive AUD treatment beyond outpatient care. The Department of Veterans Affairs (VA) delivers intensive, highly structured addiction and psychosocial treatment through residential programs. Despite the evidence supporting pharmacotherapy among the effective treatments for AUD, receipt of these medications (e.g., naltrexone, acamprosate) among patients in residential treatment programs varies widely. In order to better understand this variation, the current study examined barriers and facilitators to use of pharmacotherapy for AUD among patients in VA residential treatment programs. Semi-structured qualitative interviews with residential program management and staff were conducted and the Consolidated Framework for Implementation Research was used to guide coding and analysis of interview transcripts. Barriers to use of pharmacotherapy for AUD included cultural norms or philosophy against prescribing, lack of access to willing prescribers, lack of interest from leadership, and perceived lack of patient interest or need. Facilitators included cultural norms of openness or active promotion of pharmacotherapy; education for patients, program staff and prescribers; having prescribers on staff, and care coordination within residential treatment and with other clinic settings in and outside VA. Developing and testing improvement strategies to increase care coordination and consistent support from leadership may also yield increases in the use of pharmacotherapy for AUD among residential patients. Published by Elsevier Inc
引用
收藏
页码:38 / 43
页数:6
相关论文
共 50 条
  • [41] Impacts of COVID-19 on residential treatment programs for substance use disorder
    Pagano, Anna
    Hosakote, Sindhu
    Kapiteni, Kwinoja
    Straus, Elana R.
    Wong, Jessie
    Guydish, Joseph R.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 123
  • [42] Implementing Medication-Assisted Treatment for Opioid Use Disorder in Residential Programs
    Fareed, Ayman
    ADDICTIVE DISORDERS & THEIR TREATMENT, 2020, 19 (01) : 66 - 68
  • [43] Ketamine Treatment for Alcohol Use Disorder: A Systematic Review
    Kelson, Michael
    Burnett, Justin M.
    Matthews, Amy
    Juneja, Tony
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
  • [44] Feasibility and Acceptability of Group-Facilitated Prolonged Exposure Therapy for PTSD in VA Residential Rehabilitation Treatment Programs
    Sripada, Rebecca K.
    Rodriguez, Jessica L.
    Wright, Theodore P.
    Hyland, Jessica A.
    Walters, Heather M.
    Ganoczy, Dara
    Haft, Stephanie M.
    Smith, Erin R.
    Porter, Katherine E.
    Driesenga, Scott A.
    DeJong, Timothy M.
    Rauch, Sheila A. M.
    BEHAVIOR THERAPY, 2022, 53 (04) : 714 - 724
  • [45] Outpatient treatment of alcohol use disorder
    Molavi, Armon
    Guruge, Sulara
    Kelly, Peter
    BRITISH COLUMBIA MEDICAL JOURNAL, 2020, 62 (08): : 272 - 276
  • [46] Identification and Treatment of Alcohol Use Disorder
    Haber, Paul S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, : 258 - 266
  • [47] Barriers to Alcohol Use Disorder Treatment Among Cisgender and Transgender Individuals in the Netherlands: A Qualitative Study
    Alonso-Marmelstein, L.
    Viiri, S.
    Nagelhout, G. E.
    van Dongen, B. M.
    Kaag, A. M.
    ALCOHOLISM TREATMENT QUARTERLY, 2025,
  • [48] Outpatient continuing care after residential substance use disorder treatment in the US Veterans Health Administration: Facilitators and challenges
    Rubinsky, Anna D.
    Ellerbe, Laura S.
    Gupta, Shalini
    Phelps, Tyler E.
    Bowe, Thomas
    Burden, Jennifer L.
    Harris, Alex H. S.
    SUBSTANCE ABUSE, 2018, 39 (03) : 322 - 330
  • [49] Resistance to Temptation: The Interaction of External and Internal Control on Alcohol Use During Residential Treatment for Alcohol Use Disorder
    Soravia, Leila M.
    Schlaefli, Katrin
    Stutz, Sonja
    Roesner, Susanne
    Moggi, Franz
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2015, 39 (11) : 2209 - 2214
  • [50] Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes
    Hagedorn, Hildi J.
    Wisdom, Jennifer P.
    Gerould, Heather
    Pinsker, Erika
    Brown, Randall
    Dawes, Michael
    Dieperink, Eric
    Myrick, Donald Hugh
    Oliva, Elizabeth M.
    Wagner, Todd H.
    Harris, Alex H. S.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2019, 14 (1)